These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26720333)

  • 21. The Clinical Use of Ivabradine.
    Koruth JS; Lala A; Pinney S; Reddy VY; Dukkipati SR
    J Am Coll Cardiol; 2017 Oct; 70(14):1777-1784. PubMed ID: 28958335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R; Ceconi C
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):959-73. PubMed ID: 21878041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E; Lerebours G; Vilaine JP
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on ivabradine for heart failure.
    Borer JS; Tavazzi L
    Trends Cardiovasc Med; 2016 Jul; 26(5):444-9. PubMed ID: 26934996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ivabradine: Heart Failure and Beyond.
    Chaudhary R; Garg J; Krishnamoorthy P; Shah N; Lanier G; Martinez MW; Freudenberger R
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):335-43. PubMed ID: 26721645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heart rate in coronary syndromes and heart failure.
    Orso F; Baldasseroni S; Maggioni AP
    Prog Cardiovasc Dis; 2009; 52(1):38-45. PubMed ID: 19615492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.
    Nuding S; Ebelt H; Hoke RS; Krummenerl A; Wienke A; Müller-Werdan U; Werdan K
    Clin Res Cardiol; 2011 Oct; 100(10):915-23. PubMed ID: 21638157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ivabradine: beyond heart rate control.
    Riccioni G; Vitulano N; D'Orazio N
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Heart rate: a risk factor or an epiphenomenon?].
    Metra M; Zacà V; Lombardi C; Bugatti S; Dei Cas L
    G Ital Cardiol (Rome); 2010 Mar; 11(3):209-20. PubMed ID: 20550061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
    Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
    Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.
    Cammarano C; Silva M; Comee M; Donovan JL; Malloy MJ
    Clin Ther; 2016 Feb; 38(2):387-95. PubMed ID: 26839043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heart rate and heart failure: the role of ivabradine therapy.
    Reil JC; Böhm M
    Curr Opin Cardiol; 2013 May; 28(3):326-31. PubMed ID: 23549235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging role of ivabradine for rate control in atrial fibrillation.
    Turley SL; Francis KE; Lowe DK; Cahoon WD
    Ther Adv Cardiovasc Dis; 2016 Dec; 10(6):348-352. PubMed ID: 27659287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
    Reil JC; Reil GH; Böhm M
    Trends Cardiovasc Med; 2009 Jul; 19(5):152-7. PubMed ID: 20005474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heart rate and its reduction in chronic heart failure and beyond.
    Nikolovska Vukadinović A; Vukadinović D; Borer J; Cowie M; Komajda M; Lainscak M; Swedberg K; Böhm M
    Eur J Heart Fail; 2017 Oct; 19(10):1230-1241. PubMed ID: 28627045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure.
    Cavusoglu Y; Mert U; Nadir A; Mutlu F; Morrad B; Ulus T
    J Cardiovasc Med (Hagerstown); 2015 Sep; 16(9):603-9. PubMed ID: 24922198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ivabradine in heart failure: hope or hype?
    Deedwania PC
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):357-9. PubMed ID: 23181943
    [No Abstract]   [Full Text] [Related]  

  • 40. An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure.
    Rosa GM; Ferrero S; Ghione P; Valbusa A; Brunelli C
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):279-91. PubMed ID: 24377458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.